Natixis Acquires New Position in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Natixis purchased a new position in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 6,000 shares of the company's stock, valued at approximately $541,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IRTC. Vanguard Group Inc. increased its holdings in shares of iRhythm Technologies by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 3,136,370 shares of the company's stock valued at $282,806,000 after acquiring an additional 18,442 shares during the period. Champlain Investment Partners LLC increased its stake in iRhythm Technologies by 8.9% in the fourth quarter. Champlain Investment Partners LLC now owns 726,262 shares of the company's stock valued at $65,487,000 after purchasing an additional 59,161 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of iRhythm Technologies by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 570,048 shares of the company's stock valued at $50,991,000 after buying an additional 50,075 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of iRhythm Technologies by 111.7% during the fourth quarter. Bessemer Group Inc. now owns 568,007 shares of the company's stock worth $51,217,000 after buying an additional 299,726 shares during the period. Finally, Stephens Investment Management Group LLC grew its holdings in shares of iRhythm Technologies by 25.6% during the fourth quarter. Stephens Investment Management Group LLC now owns 502,925 shares of the company's stock worth $45,349,000 after buying an additional 102,600 shares during the last quarter.

iRhythm Technologies Price Performance

IRTC traded up $0.25 on Wednesday, hitting $106.89. 487,482 shares of the company were exchanged, compared to its average volume of 458,775. iRhythm Technologies, Inc. has a fifty-two week low of $55.92 and a fifty-two week high of $128.52. The company has a debt-to-equity ratio of 9.00, a quick ratio of 6.12 and a current ratio of 6.27. The firm has a market capitalization of $3.41 billion, a P/E ratio of -29.37 and a beta of 1.45. The business's fifty day moving average is $103.99 and its 200 day moving average is $95.59.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.30. The business had revenue of $164.33 million for the quarter, compared to analysts' expectations of $158.30 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. As a group, sell-side analysts anticipate that iRhythm Technologies, Inc. will post -1.98 EPS for the current year.

Analyst Ratings Changes

IRTC has been the subject of several analyst reports. Truist Financial upped their price objective on iRhythm Technologies from $111.00 to $145.00 and gave the company a "buy" rating in a research note on Friday, February 21st. The Goldman Sachs Group upped their price target on iRhythm Technologies from $91.00 to $124.00 and gave the stock a "neutral" rating in a research note on Monday, February 24th. StockNews.com upgraded shares of iRhythm Technologies from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Wells Fargo & Company upped their price objective on shares of iRhythm Technologies from $86.00 to $104.00 and gave the stock an "equal weight" rating in a research report on Friday, February 21st. Finally, Oppenheimer lifted their target price on shares of iRhythm Technologies from $105.00 to $120.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, iRhythm Technologies currently has an average rating of "Moderate Buy" and an average target price of $119.73.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.